The price of innovative, next generation therapies has outpaced payer budgets for som...
Read moreBe the first to receive exclusive content on the latest from the pharmaceutical and market access sector.
Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.
Get in touchThe first EU Joint Clinical Assessment (JCA) has now been published, but with so many perspectives already in the market, the real question is: what does it actually mean for your next submission?
Rather than revisiting the theory, this webinar focuses on key strategic signals revealed by the first JCA. Using the assessment of tovorafenib as a case study, we will examine what happened in practice and explore the implications for manufacturers preparing upcoming submissions.
Hosted by Paul Craddy, Charlie Hewitt & Lauren Boland
